Fosaprepitant: current options to prevent chemotherapy-induced nausea and vomiting: A review
- 作者: Ognerubov N.1
-
隶属关系:
- Derzhavin Tambov State University
- 期: 卷 24, 编号 4 (2022)
- 页面: 477-486
- 栏目: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/132982
- DOI: https://doi.org/10.26442/18151434.2022.4.202019
- ID: 132982
如何引用文章
全文:
详细
Background. Chemotherapy (CT) is a mainstay of treatment for malignant tumors. CT-induced nausea and vomiting are observed in 30–90% of patients within 0–120 h after moderate and highly emetogenic CT administration. These adverse events can severely impact the quality of treatment, daily life, and adherence to treatment, thus reducing the effectiveness of therapy and survival.
Materials and methods. The author provides the results of a systematic review of research papers, including clinical studies, on the efficacy of the neurokinin-1 receptor antagonist fosaprepitant to prevent CT-induced nausea and vomiting. Data from the PubMed database were reviewed.
Results. The prevention and treatment of CT-associated nausea and vomiting are vital during special therapy, including symptomatic therapy. International organizations recommend using a triple combination with antagonists of neurokinin-1 and 5-hydroxytryptamine-3 receptors and dexamethasone. According to the data obtained, the efficacy of fosaprepitant has been proven in delayed and general phases in several large, well-planned studies; the drug reduces the incidence of adverse events by 2.7–4.4 times compared with aprepitant.
Conclusion. Fosaprepitant is an antagonist of neurokinin-1 receptors; when administered intravenously, it rapidly converts into aprepitant. When used as part of a triple combination with 5-hydroxytryptamine-3 receptor antagonists and dexamethasone in patients receiving moderate and highly emetogenic CT leads to a higher rate of complete response when controlling nausea and vomiting. In general, fosaprepitant is well tolerated.
作者简介
Nikolai Ognerubov
Derzhavin Tambov State University
编辑信件的主要联系方式.
Email: ognerubov_n.a@mail.ru
ORCID iD: 0000-0003-4045-1247
D. Sci. (Med.), Cand. Sci. (Law), Prof.
俄罗斯联邦, Tambov参考
- Cancer fact sheets. Globocan 2020. Available at: https://gco.iarc.fr/today/fact-sheets-cancers. Accessed: 15.07.2022.
- National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2019. Available at: https://www.nccn.org. Accessed: 15.07.2022.
- Bloechl-Daum B, Deuson RR, Mavros P. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24(27):4472-8. doi: 10.1200/JCO.2006.05.6382
- Zhang B, Li XL. Adherence to clinical guidelines for prophylaxis of chemotherapy induced nausea and vomiting. Chin Hosp Pharm J. 2018;38(12):1325-9 (in Chinese). doi: 10.13286/j.cnki.chinhosppharmacyj.2018.12.19
- Hesketh PJ, Bohlke K, Lyman GH, et al. Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol. 2016;34(4):381-6. doi: 10.1200/JCO.2015.64.3635
- Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer. 2005;41(9):1278-85. doi: 10.1016/j.ejca.2005.01.024
- Tsuji D, Suzuki K, Kawasaki Y, et al. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial. Support Care Cancer. 2019;27(3):1139-47. doi: 10.1007/s00520-018-4403-y
- Mosa ASM, Hossain AM, Lavoie BJ, Yoo I. Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review. Front Pharmacol. 2020;11:329. doi: 10.3389/fphar.2020.00329
- Navari RM, Schwartzberg LS. Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. Onco Targets Ther. 2018;11:6459-78. doi: 10.2147/OTT.S158570
- Kreys ED, Kim TY, Delgado A, Koeller JM. Impact of cancer supportive care pathways compliance on emergency department visits and hospitalizations. J Oncol Pract. 2014;10(3):168-73. doi: 10.1200/JOP.2014.001376
- Dranitsaris G, Molassiotis A, Clemons M, et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol. 2017;28(6):1260-7. doi: 10.1093/annonc/mdx100
- Rojas C, Raje M, Tsukamoto T, Slusher BS. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol. 2014;722:26-37. doi: 10.1016/j.ejphar.2013.08.049
- Aogi K, Takeuchi H, Saeki T, et al. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol. 2021;26(1):1-17. doi: 10.1007/s10147-020-01818-3
- Piechotta V, Adams A, Haque M, et al. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. Cochrane Database Syst Rev. 2021;11(11):CD012775. doi: 10.1002/14651858.CD012775.pub2
- Kraut L, Fauser AA. Anti-emetics for cancer chemotherapy-induced emesis: Potential of alternative delivery systems. Drugs. 2001;61(11):1553-62. doi: 10.2165/00003495-200161110-00003
- Jordan K, Gralla R, Jahn F, Molassiotis A. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol. 2014;722:197-202. doi: 10.1016/j.ejphar.2013.09.073
- Soukop M. Management of cyclophosphamide-induced emesis over repeat courses. Oncology. 1996;53(Suppl. 1):39-45. doi: 10.1159/000227639
- Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999;17(9):2971-94. doi: 10.1200/JCO.1999.17.9.2971
- Roscoe JA, Morrow GR, Hickok JT, Stern RM. Nausea and vomiting remain a significant clinical problem: Trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage. 2000;20(2):113-21. doi: 10.1016/s0885-3924(00)00159-7
- Nakamura M, Ishiguro A, Muranaka T, et al. A prospective observational study on effect of short-term periodic steroid premedication on bone metabolism in gastrointestinal cancer (ESPRESSO-01). Oncologist. 2017;22(5):592-600. doi: 10.1634/theoncologist.2016-0308
- Celio L, Bonizzoni E, Zattarin E, et al. Impact of dexamethasonesparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomized evidence. BMC Cancer. 2019;19(1):1268. doi: 10.1186/s12885-019-6454-y
- Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38(24):2782-97. doi: 10.1200/JCO.20.01296
- Watanabe D, Iihara H, Fujii H, et al. One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis. Oncologist. 2022;27(6):e524-32. doi: 10.1093/oncolo/oyac060
- Di Maio M, Baratelli C, Bironzo P, et al. Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018;124:21-8. doi: 10.1016/j.critrevonc.2018.02.001
- Wang DS, Hu MT, Wang ZQ, et al. Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. JAMA Netw Open. 2021;4(4):e215250. doi: 10.1001/jamanetworkopen.2021.5250
- Kim JE, Jang JS, Kim JW, et al. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. Support Care Cancer. 2017;25(3):801-9. doi: 10.1007/s00520-016-3463-0
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Antiemesis, Version 2. 2020. Available at: https://www.nccn.org. Accessed: 20.10.2020.
- Javid H, Afshari AR, Avval FZ, et al. Aprepitant Promotes Caspase-Dependent Apoptotic Cell Death and G2/M Arrest through PI3K/Akt/NF-κB Axis in Cancer Stem-Like Esophageal Squamous Cell Carcinoma Spheres. BioMed Res Int. 2021;2021:8808214. doi: 10.1155/2021/8808214
- The National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Antiemesis, Version 1. 2021. Available at: https://www.nccn.org. Accessed: 20.07.2022.
- Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(Suppl. 5):v119-33. doi: 10.1093/annonc/mdw270
- Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010;18(4):423-31. doi: 10.1007/s00520-009-0680-9
- Bošnjak SM, Gralla RJ, Schwartzberg L. Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists. Support Care Cancer. 2017;25(5):1661-71. doi: 10.1007/s00520-017-3585-z
- Colon-Gonzalez F, Kraft WK. Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert Opin Drug Metab Toxicol. 2010;6(10):1277-86. doi: 10.1517/17425255.2010.513970
- Van Laere K, De Hoon J, Bormans G, et al. Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. Clin Pharmacol Ther. 2012;92(2):243-50. doi: 10.1038/clpt.2012.62
- Boccia R, Geller RB, Clendeninn N, Ottoboni T. Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study. Future Oncol. 2019;15(3):297-303. doi: 10.2217/fon-2018-0662
- Dranitsaris G, Moezi M, Dobson K, et al. A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer. 2022;30(8):6649-58. doi: 10.1007/s00520-022-07082-7
- Sugawara S, Inui N, Kanehara M, et al. Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Cancer. 2019;125(22):4076-83. doi: 10.1002/cncr.32429
- Weinstein C, Jordan K, Green SA, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol. 2016;27:172-8. doi: 10.1093/annonc/mdv482
- National Comprehensive Cancer Network. Antiemesis: NCCN clinical practice guidelines in oncology, Version 2. 2016. Available at: http://www.nccn.org. Accessed: 8.07.2016.
- Saito H, Yoshizawa H, Yoshimori K, et al. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol. 2013;24(4):1067-73. doi: 10.1093/annonc/mds541
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis, Version 3. 2018. Available at: www.nccn.org/patients. Accessed: 11.06.2018.
- Grunberg S, Chua D, Maru A, et al. Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol–EASE. J Clin Oncol. 2011;29(11):1495-501. doi: 10.1200/JCO.2010.31.7859
- Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189-98. doi: 10.1200/JCO.2010.34.4614
- Weinstein C, Jordan K, Green S, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type. BMC Cancer. 2020;20(1):918. doi: 10.1186/s12885-020-07259-5
- Yang LQ, Sun XC, Qin SK, et al. Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study. Eur J Cancer Care (Engl). 2017;26(6):e12668. doi: 10.1111/ecc.12668
- Gao A, Guan S, Sun Y, et al. Prolonged usage of fosaprepitant for prevention of delayed CINV in patients receiving highly emetogenic chemotherapy. Preprint. 2022. doi: 10.21203/rs.3.rs-1737681/v1
- Lupin receives U.S. FDA approval for fosaprepitant for injection. September 6, 2019. Available at: https://www.lupin.com/lupin-receives-u-s-fda-approval-for-fosaprepitant-for-injection/ Accessed: 27.08.2021.
- Novadoz Pharmaceuticals/MSN Labs receives FDA clearance for fosaprepitant and decitabine the company’s first generic specialty injectable products. September 5, 2019. Available at: https://www.prnewswire.com/news-releases/novadoz-pharmaceuticalsmsn-labs-receives-fda-clearance-for-fosaprepitant-and-decitabine-the-companys-first-generic-specialty-injectable-products-300912919.html. Accessed: 27.08.2021.
- Craver C, Gayle J, Balu S, Buchner D. Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ. 2011;14(1):87-98. doi: 10.3111/13696998.2010.547237
- Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer. 2011;19(1):131-40. doi: 10.1007/s00520-009-0797-x
- Xu X, Bao Y, Xu K, et al. Economic Value of Fosaprepitant-Containing Regimen in the Prevention of Chemotherapy-Induced Nausea and Vomiting in China: Cost-Effectiveness and Budget Impact Analysis. Front Public Health. 2022;10:913129. doi: 10.3389/fpubh.2022.913129